HIROYUKI HAMADA—Since people’s minds and their collective mode of operations are deeply indoctrinated to be a part of the capitalist structure, any crisis would strengthen the fundamental integrity of the structure. I heard a Trump supporter saying that “people should be shaking up a little”. That’s actually a very appropriate description. You shake their ground, people try to hold onto whatever they think is a solid structure. Some of us might however try to hold onto a Marxist perspective for example. That of course provokes triggering reactions by those who go along with the capitalist framework, because they are particularly threatened, sensing that their entire belief system might fall.
-
-
ALICE McCARTHY—According to the World Health Organization, older people and people with preexisting medical conditions appear to be more vulnerable to becoming severely ill with COVID-19.
“Elderly individuals have a different immune system than healthy middle-aged adults and often do not respond as robustly to immunization, so a one-size vaccine does not fit all,” said Ofer Levy, professor of pediatrics at Harvard Medical School and director of the PVP.
-
Read it in your language • Lealo en su idioma • Lisez-le dans votre…
-
The U.S. Food and Drug Administration (FDA) took significant steps to increase the availability of ventilators and other respiratory devices, to support patients with respiratory failure or difficulty breathing. “Hospitals and other healthcare providers can repurpose (breathing) machines they have to serve as ventilators.” With a predicted shortfall of hospital ventilators needed to treat people diagnosed with COVID-19 disease with breathing problems, the FDA has authorized the use of Continuous Positive Airway Pressure (CPAP) and similar devices to help cover the forecasted shortage.
-
When China’s health leadership announced they have found the anti-influenza drug Avigan (Favipiravir) effective in treating COVID-19 disease in adult patients, Japan was expected to follow. China’s positive reception of Avigan (Favipiravir) contrasts with Japan’s continued reservations. Avigan initially obtained regulatory approval in Japan during 2014. Since then, clinical studies have indicated Avigan (Favipiravir) may cause serious side effects. However, on March 17, 2020, Zhang Xinmin, China’s director of the National Center for Biotechnology Development said ‘Avigan (Favipiravir) was found to be effective in clinical trials during 2020.’ These studies in China concluded this medicine was effective in treating coronavirus-related symptoms and had no obvious side effects.
